BioSpace News Archive

Drug Development

Positive Feedback From FDA Significantly Benefits Ongoing NefIgArd Pivotal Phase 3 Study

Calliditas Therapeutics AB announced that it has obtained written feedback from the US Food and Drug Administration that will have a significant impact on the ongoing pivotal Phase 3 study, NefIgArd, with Calliditas’ leading drug candidate Nefecon for the chronic autoimmune kidney disease IgA Nephropathy.

September 3, 2019
·
3 min read
Business

Velabs Therapeutics announces strategic partnership with alytas therapeutics to develop a novel immune-based therapy for obesity

Velabs Therapeutics GmbH announces that it has entered into a partnership agreement with alytas therapeutics GmbH, to jointly develop modulatory and functional antibodies for a novel immune-based therapy against obesity.

September 3, 2019
·
3 min read
Arkivum Provides Pioneering e-Archive to Idorsia Pharmaceuticals Delivering GxP Compliant Long-term Access to Valuable Product and Clinical Trial Data

Arkivum announced that Idorsia Pharmaceuticals, headquartered near Basel, Switzerland; has selected Arkivum to safeguard and digitally preserve their valuable research and clinical trial data.

September 3, 2019
·
3 min read
Business

The Danger in America’s Medicine Cabinets: Recovery Centers of America and Mothers Against Prescription Drug Abuse Announce New Partnership to End Prescription Drug Abuse

RCA and MAPDA Working Together to Bring Awareness about the Problem of Leftover Prescription Drugs

September 3, 2019
·
3 min read
Drug Development

Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa

Aridis Pharmaceuticals, Inc. announced results from the Company’s first-in-patient Phase 2 clinical trial evaluating AR-105, a fully human IgG1 monoclonal antibody for the treatment of ventilator-associated pneumonia caused by gram-negative Pseudomonas aeruginosa (P. aeruginosa)

September 3, 2019
·
10 min read
BioForest

DENclarity is the First and Best Dental Monitor for the Operatory

When ExorVision was founded, they worked directly with dentists to produce a custom-built monitor that addressed the high safety and quality standards required for the operatory environment.

September 3, 2019
·
1 min read
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States

Endo International plc announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck’s Noxafil® delayed-release tablets, 100 mg.

September 3, 2019
·
3 min read
Deals

NovaBay Pharmaceuticals to Present at Two Investment Conferences in September 2019

NovaBay® Pharmaceuticals, Inc. announces that management will present at two upcoming investment conferences

September 3, 2019
·
2 min read
Deals

Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September 2019

Spectrum Pharmaceuticals announced that an overview of the company’s business strategy and development-stage programs will be given at two upcoming conferences being held in New York on September 10th and September 11th.

September 3, 2019
·
3 min read
BioMidwest

Exicure to Present at Upcoming Investor Conferences

Exicure, Inc. announced presentations at the following investor conferences during the months of September and early October

September 3, 2019
·
1 min read